# KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma

> **NCT05723432** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai Kanda Biotechnology Co., Ltd.** · enrollment: 84 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** KD6001
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT05723432
- **Lead sponsor:** Shanghai Kanda Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-22
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2023-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05723432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05723432, "KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05723432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*